Lawyers for marijuana reform opponents that are participating in a Drug Enforcement Administration (DEA) hearing on the Trump administration’s cannabis rescheduling proposal put significant focus on the second day of the proceedings on pressing a government witness about recently adopted changes to an analysis used to determine whether drugs have accepted medical value.
A separate government witness who began his testimony on Tuesday focused on cannabis’s role in treating pain patients and its relative safety compared to opioids.
Under federal law, drugs that have a currently accepted medical use (CAMU) cannot be classified in Schedule I, the most restrictive category. For years, officials had used a five-part test to determine a substance’s medical utility that involved an analysis of whether its chemistry is known and reproducible, safety studies, research proving efficacy, acceptance by qualified experts and widely available scientific evidence.
But in 2023 to evaluate marijuana, they switched to a new two-part analysis that looks at whether there is widespread, current experience with medical use of the substance by licensed health care providers operating in accordance with state laws and, if so, whether there is some credible scientific support for at least one of the medical conditions it is being
Read full article on Marijuana Moment
